Chemotherapy represents one of the maximum efficacious strategies to deal with cancer sufferers, bringing effective changes at least quickly even to those sufferers with incurable malignancies. However, maximum patients respond poorly after a sure quantity of cycles of treatment due to the development of drug resistance. Resistance to drugs administrated to cancer sufferers significantly limits the advantages that patients can reap and is still a severe scientific problem. Among the mechanisms that have been uncovered to mediate anti-cancer drug resistance, the Hippo signaling pathway is gaining growing interest due to the brilliant oncogenic sports of its additives (as an instance, YAP and TAZ) and their druggable residences. Hippo pathway changed into to start with recognized via genetic displays for genes regulating organ size in fruitflies. Recent studies have highlighted the role of Hippo signaling as a key regulator of homeostasis, and in tumorigenesis. Hippo pathway is constructed from genes that act as tumor suppressor genes like hippo (hpo) and warts (wts), and oncogenes like yorkie (yki). YAP and TAZ are associated mammalian homologs of Drosophila Yki that act as effectors of the Hippo pathway. Hippo signaling deficiency can cause YAP- or TAZ-established oncogene dependency for cancer cells.